Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Healthcare and Social Assistance

>>

North America Monoclonal Antibodies mAbs Market


North America Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity

Report code: SDMRHE1613138 | Industry: Healthcare and Social Assistance | Published On: 44560


North America monoclonal antibodies market is projected to grow by 10.4% annually in the forecast period and reach $133.4 billion by 2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Highlighted with 24 tables and 48 figures, this 102-page report “North America Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country.

Based on Source, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Human
• Humanized
• Chimeric
• Murine

Based on Category, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Branded mAbs
• Biosimilar mAbs

Based on Production Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• In Vitro Production
• In Vivo Production

Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications

By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospitals
• Research Institutes
• Other End Users

Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1  Introduction 7
1.1  Industry  Definition  and  Research  Scope 7
1.1.1  Industry  Definition 7
1.1.2  Research  Scope 8
1.2  Research  Methodology 11
1.2.1  Overview  of  Market  Research  Methodology 11
1.2.2  Market  Assumption 12
1.2.3  Secondary  Data 12
1.2.4  Primary  Data 12
1.2.5  Data  Filtration  and  Model  Design 13
1.2.6  Market  Size/Share  Estimation 14
1.2.7  Research  Limitations 15
1.3  Executive  Summary 16
2  Market  Overview  and  Dynamics 19
2.1  Market  Size  and  Forecast 19
2.1.1  Impact  of  COVID-19  on  World  Economy 20
2.1.2  Impact  of  COVID-19  on  the  Market 22
2.2  Major  Growth  Drivers 24
2.3  Market  Restraints  and  Challenges 29
2.4  Emerging  Opportunities  and  Market  Trends 32
2.5  Porter’s  Fiver  Forces  Analysis 36
3  Segmentation  of  North  America  Market  by  Source 40
3.1  Market  Overview  by  Source 40
3.2  Human 42
3.3  Humanized 43
3.4  Chimeric 44
3.5  Murine 45
4  Segmentation  of  North  America  Market  by  Category 46
4.1  Market  Overview  by  Category 46
4.2  Branded  mAbs 48
4.3  Biosimilar  mAbs 49
5  Segmentation  of  North  America  Market  by  Production  Type 50
5.1  Market  Overview  by  Production  Type 50
5.2  In  Vitro  Production 52
5.3  In  Vivo  Production 53
6  Segmentation  of  North  America  Market  by  Application 54
6.1  Market  Overview  by  Application 54
6.2  Cancer 56
6.2.1  Breast  Cancer 58
6.2.2  Colorectal  Cancer 59
6.2.3  Lung  Cancer 60
6.2.4  Ovarian  Cancer 61
6.2.5  Other  Cancer  Types 62
6.3  Autoimmune  Diseases 63
6.4  Inflammatory  Diseases 64
6.5  Infectious  Diseases 65
6.6  Other  Applications 66
7  Segmentation  of  North  America  Market  by  End  User 67
7.1  Market  Overview  by  End  User 67
7.2  Hospitals 69
7.3  Research  Institutes 70
7.4  Other  End  Users 71
8  North  America  Market  2019-2030  by  Country 72
8.1  Overview  of  North  America  Market 72
8.2  U.S. 75
8.3  Canada 78
8.4  Mexico 80
9  Competitive  Landscape 82
9.1  Overview  of  Key  Vendors 82
9.2  New  Product  Launch,  Partnership,  Investment,  and  M&A 85
9.3  Company  Profiles 86
Abbott  Laboratories 86
AbbVie,  Inc. 88
Amgen  Inc. 89
AstraZeneca  plc 90
Bayer  AG 91
Bristol-Myers  Squibb  Company 92
Eli  Lilly 93
F.  Hoffmann-La  Roche  Ltd. 94
GlaxoSmithKline  Plc 95
Johnson  &  Johnson 96
Merck  &  Co.,  Inc. 97
Mylan  N.V 98
Norvatis  AG 99
Pfizer 100
Sanofi  S.A. 101
RELATED  REPORTS 102
List of Tables:

Table 1. Snapshot of North America Monoclonal Antibodies Market in Balanced Perspective, 2019-2030 17
Table 2. Growth Rate of World GDP, 2020-2022 21
Table 3. World Health Spending by Region, $ bn, 2013-2020 28
Table 4. Main Product Trends and Market Opportunities in North America Monoclonal Antibodies Market 32
Table 5. North America Monoclonal Antibodies Market by Source, 2019-2030, $ bn 40
Table 6. North America Monoclonal Antibodies Market by Category, 2019-2030, $ bn 46
Table 7. North America Monoclonal Antibodies Market by Production Type, 2019-2030, $ bn 50
Table 8. North America Monoclonal Antibodies Market by Application, 2019-2030, $ bn 54
Table 9. North America Monoclonal Antibodies Market: Cancer Therapy by Type, 2019-2030, $ bn 57
Table 10. North America Monoclonal Antibodies Market by End User, 2019-2030, $ bn 67
Table 11. North America Monoclonal Antibodies Market by Country, 2019-2030, $ bn 73
Table 12. U.S. Monoclonal Antibodies Market by Source, 2019-2030, $ bn 77
Table 13. U.S. Monoclonal Antibodies Market by Application, 2019-2030, $ bn 77
Table 14. U.S. Monoclonal Antibodies Market by End User, 2019-2030, $ bn 77
Table 15. Canada Monoclonal Antibodies Market by Source, 2019-2030, $ bn 79
Table 16. Canada Monoclonal Antibodies Market by Application, 2019-2030, $ bn 79
Table 17. Canada Monoclonal Antibodies Market by End User, 2019-2030, $ bn 79
Table 18. Mexico Monoclonal Antibodies Market by Source, 2019-2030, $ bn 81
Table 19. Mexico Monoclonal Antibodies Market by Application, 2019-2030, $ bn 81
Table 20. Mexico Monoclonal Antibodies Market by End User, 2019-2030, $ bn 81
Table 21. Abbott Laboratories: Company Snapshot 86
Table 22. Abbott Laboratories: Business Segmentation 86
Table 23. Abbott Laboratories: Product Portfolio 87
Table 24. Abbott Laboratories: Revenue, 2018-2020, $ bn 87
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT